{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:05:44Z","timestamp":1794265544660,"version":"4.9.0"},"reference-count":102,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>There is debate on the role of glial fibrillary acidic protein (GFAP) as a reliable biomarker in multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), and its potential to reflect disease progression. This review aimed to investigate the role of GFAP in MS and NMOSD. A systematic search of electronic databases, including PubMed, Embase, Scopus, and Web of Sciences, was conducted up to 20 December 2023 to identify studies that measured GFAP levels in people with MS (PwMS) and people with NMOSD (PwNMOSD). R software version 4.3.3. with the random-effect model was used to pool the effect size with its 95% confidence interval (CI). Of 4109 studies, 49 studies met our inclusion criteria encompassing 3491 PwMS, 849 PwNMOSD, and 1046 healthy controls (HCs). The analyses indicated that the cerebrospinal fluid level of GFAP (cGFAP) and serum level of GFAP (sGFAP) were significantly higher in PwMS than HCs (SMD = 0.7, 95% CI: 0.54 to 0.86, p &lt; 0.001, I2 = 29%, and SMD = 0.54, 95% CI: 0.1 to 0.99, p = 0.02, I2 = 90%, respectively). The sGFAP was significantly higher in PwNMOSD than in HCs (SMD = 0.9, 95% CI: 0.73 to 1.07, p &lt; 0.001, I2 = 10%). Among PwMS, the Expanded Disability Status Scale (EDSS) exhibited significant correlations with cGFAP (r = 0.43, 95% CI: 0.26 to 0.59, p &lt; 0.001, I2 = 91%) and sGFAP (r = 0.36, 95% CI: 0.23 to 0.49, p &lt; 0.001, I2 = 78%). Regarding that GFAP is increased in MS and NMOSD and has correlations with disease features, it can be a potential biomarker in MS and NMOSD and indicate the disease progression and disability in these disorders.<\/jats:p>","DOI":"10.3390\/medicina60071050","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T07:20:06Z","timestamp":1719386406000},"page":"1050","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The Role of Glial Fibrillary Acidic Protein as a Biomarker in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"60","author":[{"given":"Aysa","family":"Shaygannejad","sequence":"first","affiliation":[{"name":"Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan 81839-83434, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3516-119X","authenticated-orcid":false,"given":"Nazanin","family":"Rafiei","sequence":"additional","affiliation":[{"name":"School of Medicine, Isfahan University of Medical Sciences, Isfahan 81746-73461, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5738-7419","authenticated-orcid":false,"given":"Saeed","family":"Vaheb","sequence":"additional","affiliation":[{"name":"Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan 81839-83434, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9112-9544","authenticated-orcid":false,"given":"Mohammad","family":"Yazdan Panah","sequence":"additional","affiliation":[{"name":"Student Research Committee, Shahrekord University of Medical Sciences, Shahrekord 88157-13471, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Shaygannejad","sequence":"additional","affiliation":[{"name":"Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan 81839-83434, Iran"},{"name":"Department of Neurology, Isfahan University of Medical Sciences, Isfahan 81746-73461, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3756-2985","authenticated-orcid":false,"given":"Omid","family":"Mirmosayyeb","sequence":"additional","affiliation":[{"name":"Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan 81839-83434, Iran"},{"name":"Department of Neurology, Isfahan University of Medical Sciences, Isfahan 81746-73461, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"key":"ref_1","unstructured":"Tafti, D., Ehsan, M., and Xixis, K.L. (2024, May 01). Multiple Sclerosis. [Updated 2022 Sep 7], StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK499849\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"a028936","DOI":"10.1101\/cshperspect.a028936","article-title":"Multiple Sclerosis Pathology","volume":"8","author":"Lassmann","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: From pathophysiology to therapeutic strategies","volume":"18","author":"Correale","year":"2021","journal-title":"J. Neuroinflamm."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Hor, J.Y., Asgari, N., Nakashima, I., Broadley, S.A., Leite, M.I., Kissani, N., Jacob, A., Marignier, R., Weinshenker, B.G., and Paul, F. (2020). Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Front. Neurol., 11.","DOI":"10.3389\/fneur.2020.00501"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s10072-023-06617-y","article-title":"Worldwide prevalence of neuromyelitis optica spectrum disorder (NMOSD) and neuromyelitis optica (NMO): A systematic review and meta-analysis","volume":"44","author":"Bagherieh","year":"2023","journal-title":"Neurol. Sci."},{"key":"ref_8","unstructured":"Shumway, C.L., Patel, B.C., Tripathy, K., and De Jesus, O. (2024, May 01). Neuromyelitis Optica Spectrum Disorder (NMOSD). [Updated 2024 Jan 8], StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK572108\/."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1177\/1352458517726592","article-title":"Defining active progressive multiple sclerosis","volume":"23","author":"Sellebjerg","year":"2017","journal-title":"Mult. Scler."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/135245859800400307","article-title":"MBP, anti-MBP and anti-PLP antibodies, and intrathecal complement activation in multiple sclerosis","volume":"4","author":"Sellebjerg","year":"1998","journal-title":"Mult. Scler."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.neulet.2017.07.050","article-title":"GFAP in early multiple sclerosis: A biomarker for inflammation","volume":"657","author":"Kassubek","year":"2017","journal-title":"Neurosci. Lett."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1023\/A:1007677003387","article-title":"Glial fibrillary acidic protein: GFAP-thirty-one years (1969\u20132000)","volume":"25","author":"Eng","year":"2000","journal-title":"Neurochem. Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Kim, H., Lee, E.-J., Lim, Y.-M., and Kim, K.-K. (2022). Glial Fibrillary Acidic Protein in Blood as a Disease Biomarker of Neuromyelitis Optica Spectrum Disorders. Front. Neurol., 13.","DOI":"10.3389\/fneur.2022.865730"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"14798","DOI":"10.1038\/s41598-018-33158-8","article-title":"Serum GFAP as a biomarker for disease severity in multiple sclerosis","volume":"8","author":"Abdelhak","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/jnnp-2019-322286","article-title":"CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD","volume":"91","author":"Kleerekooper","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1750-3639.1996.tb00854.x","article-title":"Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis","volume":"6","author":"Lucchinetti","year":"1996","journal-title":"Brain Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/brain\/117.6.1311","article-title":"Patterns of oligodendroglia pathology in multiple sclerosis","volume":"117","author":"Ozawa","year":"1994","journal-title":"Brain"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/brain\/awf165","article-title":"Markers for different glial cell responses in multiple sclerosis: Clinical and pathological correlations","volume":"125","author":"Petzold","year":"2002","journal-title":"Brain"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ana.26067","article-title":"Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker","volume":"89","author":"Aktas","year":"2021","journal-title":"Ann. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jns.2012.02.012","article-title":"Serum GFAP levels in optic neuropathies","volume":"317","author":"Storoni","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.brainres.2014.12.027","article-title":"Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease","volume":"1600","author":"Petzold","year":"2015","journal-title":"Brain Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12974-022-02450-w","article-title":"CSF GFAP levels in double seronegative neuromyelitis optica spectrum disorder: No evidence of astrocyte damage","volume":"19","author":"Hyun","year":"2022","journal-title":"J. Neuroinflamm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/sim.8781","article-title":"Evaluation of various estimators for standardized mean difference in meta-analysis","volume":"40","author":"Lin","year":"2021","journal-title":"Stat Med"},{"key":"ref_26","first-page":"700","article-title":"Interpreting estimates of treatment effects: Implications for managed care","volume":"33","author":"Faraone","year":"2008","journal-title":"Pharm. Ther."},{"key":"ref_27","unstructured":"Lalibert\u00e9, E., and Lalibert\u00e9, M. (2009). Package \u2018Metacor\u2019, The R Foundation. Version 1.0-2.1."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1213\/ANE.0000000000002864","article-title":"Correlation Coefficients: Appropriate Use and Interpretation","volume":"126","author":"Schober","year":"2018","journal-title":"Anesth. Analg."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<841::AID-SIM781>3.0.CO;2-D","article-title":"Detecting and describing heterogeneity in meta-analysis","volume":"17","author":"Hardy","year":"1998","journal-title":"Stat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/bmj.333.7568.597","article-title":"The case of the misleading funnel plot","volume":"333","author":"Lau","year":"2006","journal-title":"BMJ"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis: Guidelines on choice of axis","volume":"54","author":"Sterne","year":"2001","journal-title":"J. Clin. Epidemiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Azzolini, F., Gilio, L., Pavone, L., Iezzi, E., Dolcetti, E., Bruno, A., Buttari, F., Musella, A., Mandolesi, G., and Guadalupi, L. (2022). Neuroinflammation Is Associated with GFAP and sTREM2 Levels in Multiple Sclerosis. Biomolecules, 12.","DOI":"10.3390\/biom12020222"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Novakova, L., Axelsson, M., Malmestr\u00f6m, C., Imberg, H., Elias, O., Zetterberg, H., Nerman, O., and Lycke, J. (2018). Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0194828"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/jnc.13881","article-title":"Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis","volume":"141","author":"Novakova","year":"2017","journal-title":"J. Neurochem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/ene.13274","article-title":"Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis","volume":"24","author":"Tisell","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/ane.12239","article-title":"Assessing tissue damage in multiple sclerosis: A biomarker approach","volume":"130","author":"Burman","year":"2014","journal-title":"Acta Neurol. Scand."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1352458513490544","article-title":"Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis","volume":"20","author":"Axelsson","year":"2014","journal-title":"Mult. Scler."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10072-012-0974-4","article-title":"Cytoskeletal proteins in the cerebrospinal fluid as biomarker of multiple sclerosis","volume":"34","author":"Madeddu","year":"2013","journal-title":"Neurol. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/ana.22247","article-title":"Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab","volume":"69","author":"Gunnarsson","year":"2011","journal-title":"Ann. Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/s00415-010-5863-2","article-title":"Glial fibrillary acidic protein: A potential biomarker for progression in multiple sclerosis","volume":"258","author":"Axelsson","year":"2011","journal-title":"J. Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/jnnp.2008.150698","article-title":"Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: An astrocytic damage marker","volume":"80","author":"Misu","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1212\/01.WNL.0000142988.49341.D1","article-title":"Neurofilament and glial fibrillary acidic protein in multiple sclerosis","volume":"63","author":"Norgren","year":"2004","journal-title":"Neurology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1034\/j.1600-0404.2003.00197.x","article-title":"Cerebrospinal fluid markers in MS patients and their healthy siblings","volume":"109","author":"Haghighi","year":"2004","journal-title":"Acta Neurol. Scand."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1212\/01.WNL.0000098880.19793.B6","article-title":"Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS","volume":"61","author":"Haghighi","year":"2003","journal-title":"Neurology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e16077","DOI":"10.1111\/ene.16077","article-title":"Association of magnetic resonance imaging phenotypes and serum biomarker levels with treatment response and long-term disease outcomes in multiple sclerosis patients","volume":"31","author":"Midaglia","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1111\/ene.15865","article-title":"Relevance of dedicated multiple sclerosis serum biomarkers in predicting contrast enhancement with gadolinium: Results from the REDUCE-GAD trial","volume":"30","author":"Schaefer","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e200078","DOI":"10.1212\/NXI.0000000000200078","article-title":"Neuroaxonal and Glial Markers in Patients of the Same Age with Multiple Sclerosis","volume":"10","author":"Loonstra","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"578218","DOI":"10.1016\/j.jneuroim.2023.578218","article-title":"Serum neurofilament light chain predicts spinal cord atrophy in neuromyelitis optica spectrum disorder","volume":"384","author":"Li","year":"2023","journal-title":"J. Neuroimmunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"fcad183","DOI":"10.1093\/braincomms\/fcad183","article-title":"Proteomics and relationship with axonal pathology in multiple sclerosis: 5-year diffusion tensor imaging study","volume":"5","author":"Jakimovski","year":"2023","journal-title":"Brain Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"104695","DOI":"10.1016\/j.msard.2023.104695","article-title":"Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes","volume":"74","author":"Bose","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e200052","DOI":"10.1212\/NXI.0000000000200052","article-title":"Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients with Progressive Multiple Sclerosis","volume":"10","author":"Barro","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_54","first-page":"1599","article-title":"Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing\u2013remitting multiple sclerosis: A 20-year follow-up cohort","volume":"271","author":"Bau","year":"2023","journal-title":"J. Neurol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/acn3.51969","article-title":"Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis","volume":"11","author":"Abdelhak","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"103535","DOI":"10.1016\/j.msard.2022.103535","article-title":"High or increasing serum NfL is predictive of impending multiple sclerosis relapses","volume":"59","author":"Thebault","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1177\/13524585221094224","article-title":"Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis","volume":"28","author":"Pauwels","year":"2022","journal-title":"Mult. Scler. J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1177\/13524585211024978","article-title":"Longitudinal follow-up of serum biomarkers in patients with neuromyelitis optica spectrum disorder","volume":"28","author":"Kim","year":"2022","journal-title":"Mult. Scler."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1177\/13524585211028831","article-title":"Optical coherence tomography angiography indicates subclinical retinal disease in neuromyelitis optica spectrum disorders","volume":"28","author":"Aly","year":"2022","journal-title":"Mult. Scler."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"17562864211054952","DOI":"10.1177\/17562864211054952","article-title":"Longitudinal treatment responsiveness on plasma neurofilament light chain and glial fibrillary acidic protein levels in neuromyelitis optica spectrum disorder","volume":"14","author":"Zhang","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12974-021-02138-7","article-title":"Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder","volume":"18","author":"Schindler","year":"2021","journal-title":"J. Neuroinflamm."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"102810","DOI":"10.1016\/j.msard.2021.102810","article-title":"Increased serum glial fibrillary acidic protein associates with microstructural white matter damage in multiple sclerosis: GFAP and DTI","volume":"50","author":"Saraste","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"103280","DOI":"10.1016\/j.msard.2021.103280","article-title":"Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis","volume":"56","author":"Niiranen","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/jnc.15478","article-title":"Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study","volume":"159","author":"Liu","year":"2021","journal-title":"J. Neurochem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"577541","DOI":"10.1016\/j.jneuroim.2021.577541","article-title":"Profiling serum neurofilament light chain and glial fibrillary acidic protein in primary progressive multiple sclerosis","volume":"354","author":"Giarraputo","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Chang, X., Huang, W., Wang, L., ZhangBao, J., Zhou, L., Lu, C., Wang, M., Yu, J., Li, H., and Li, Y. (2021). Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.647618"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e708","DOI":"10.1212\/NXI.0000000000000708","article-title":"Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"7","author":"Kim","year":"2020","journal-title":"Neurol.-Neuroimmunol. Neuroinflamm."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/acn3.51070","article-title":"Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases","volume":"7","author":"Lee","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_69","first-page":"2492","article-title":"Serum glial fibrillary acidic protein is a good marker for the diagnosis of devic\u2019s disease","volume":"12","author":"Sharquie","year":"2020","journal-title":"Int. J. Pharm. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"10923","DOI":"10.1038\/s41598-020-67934-2","article-title":"Serum GFAP in multiple sclerosis: Correlation with disease type and MRI markers of disease severity","volume":"10","author":"Ayrignac","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4274\/imj.galenos.2019.75002","article-title":"The Predictive Role of Neurobiochemical Markers in Multiple Sclerosis","volume":"21","author":"Oguz","year":"2020","journal-title":"Istanb. Med. J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"102861","DOI":"10.1016\/j.msard.2021.102861","article-title":"A pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: Evaluation of cerebrospinal fluid penetration and the effects on exploratory biomarkers","volume":"51","author":"Edwards","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Huss, A., Otto, M., Senel, M., Ludolph, A.C., Abdelhak, A., and Tumani, H. (2020). A Score Based on NfL and Glial Markers May Differentiate Between Relapsing-Remitting and Progressive MS Course. Front. Neurol., 11.","DOI":"10.3389\/fneur.2020.00608"},{"key":"ref_74","first-page":"113","article-title":"Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort","volume":"22","author":"Kalatha","year":"2019","journal-title":"Hell. J. Nucl. Med."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Abdelhak, A., Hottenrott, T., Morenas-Rodr\u00edguez, E., Su\u00e1rez-Calvet, M., Zettl, U.K., Haass, C., Meuth, S.G., Rauer, S., Otto, M., and Tumani, H. (2019). Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?. Front. Neurol., 10.","DOI":"10.3389\/fneur.2019.00280"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1212\/WNL.0b013e3181e2414b","article-title":"Astrocytic damage is far more severe than demyelination in NMO: A clinical CSF biomarker study","volume":"75","author":"Takano","year":"2010","journal-title":"Neurology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e1299","DOI":"10.1212\/WNL.0000000000008160","article-title":"Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD","volume":"93","author":"Watanabe","year":"2019","journal-title":"Neurology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1515\/revneuro-2020-0145","article-title":"Neuronal and glial CSF biomarkers in multiple sclerosis: A systematic review and meta-analysis","volume":"32","author":"Momtazmanesh","year":"2021","journal-title":"Rev. Neurosci."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Linker, R.A., Brechlin, P., Jesse, S., Steinacker, P., Lee, D.H., Asif, A.R., Jahn, O., Tumani, H., Gold, R., and Otto, M. (2009). Proteome profiling in murine models of multiple sclerosis: Identification of stage specific markers and culprits for tissue damage. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0007624"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1523\/JNEUROSCI.5480-05.2006","article-title":"Induction of glial fibrillary acidic protein expression in astrocytes by nitric oxide","volume":"26","author":"Brahmachari","year":"2006","journal-title":"J. Neurosci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.tins.2015.04.003","article-title":"Glial fibrillary acidic protein: From intermediate filament assembly and gliosis to neurobiomarker","volume":"38","author":"Yang","year":"2015","journal-title":"Trends Neurosci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/nrgastro.2012.138","article-title":"Novel functional roles for enteric glia in the gastrointestinal tract","volume":"9","author":"Gulbransen","year":"2012","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1212\/WNL.27.10.911","article-title":"Myelin encephalitogenic protein fragments in cerebrospinal fluid of persons with multiple sclerosis","volume":"27","author":"Whitaker","year":"1977","journal-title":"Neurology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/glia.22443","article-title":"The astrocyte in multiple sclerosis revisited","volume":"61","author":"Brosnan","year":"2013","journal-title":"Glia"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Aharoni, R., Eilam, R., and Arnon, R. (2021). Astrocytes in Multiple Sclerosis\u2014Essential Constituents with Diverse Multifaceted Functions. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115904"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41392-023-01628-9","article-title":"Astrocytes in human central nervous system diseases: A frontier for new therapies","volume":"8","author":"Verkhratsky","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.tins.2009.08.002","article-title":"Molecular dissection of reactive astrogliosis and glial scar formation","volume":"32","author":"Sofroniew","year":"2009","journal-title":"Trends Neurosci."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Ponath, G., Park, C., and Pitt, D. (2018). The Role of Astrocytes in Multiple Sclerosis. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00217"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2174\/1568010054022051","article-title":"Prostaglandins and cyclooxygenases in glial cells during brain inflammation","volume":"4","author":"Tzeng","year":"2005","journal-title":"Curr. Drug Targets-Inflamm. Allergy"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0006-8993(71)90668-8","article-title":"An acidic protein isolated from fibrous astrocytes","volume":"28","author":"Eng","year":"1971","journal-title":"Brain Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s13054-015-1081-8","article-title":"Glial fibrillary acidic protein as a biomarker in severe traumatic brain injury patients: A prospective cohort study","volume":"19","author":"Lei","year":"2015","journal-title":"Crit. Care"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Lin, J., Ou, R., Li, C., Hou, Y., Zhang, L., Wei, Q., Pang, D., Liu, K., Jiang, Q., and Yang, T. (2023). Plasma glial fibrillary acidic protein as a biomarker of disease progression in Parkinson\u2019s disease: A prospective cohort study. BMC Med., 21.","DOI":"10.1186\/s12916-023-03120-1"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"102870","DOI":"10.1016\/j.msard.2021.102870","article-title":"A candidate biomarker of glial fibrillary acidic protein in CSF and blood in differentiating multiple sclerosis and its subtypes: A systematic review and meta-analysis","volume":"51","author":"Sun","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"17565","DOI":"10.3390\/ijms160817565","article-title":"Brain-specific cytoskeletal damage markers in cerebrospinal fluid: Is there a common pattern between amyotrophic lateral sclerosis and primary progressive multiple sclerosis?","volume":"16","author":"Abdelhak","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1093\/brain\/awf235","article-title":"Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time","volume":"125","author":"Kuhlmann","year":"2002","journal-title":"Brain"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/1352458518819380","article-title":"Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity","volume":"26","author":"Rissanen","year":"2020","journal-title":"Mult. Scler. J."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1212\/NXI.0000000000000110","article-title":"Aquaporin-4 autoimmunity","volume":"2","author":"Zekeridou","year":"2015","journal-title":"Neuroimmunol. Neuroinflamm."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1172\/JCI38003","article-title":"Dysfunctions of neuronal and glial intermediate filaments in disease","volume":"119","author":"Liem","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_100","first-page":"109","article-title":"Peripheral markers of brain damage and blood-brain barrier dysfunction","volume":"21","author":"Marchi","year":"2003","journal-title":"Restor. Neurol. Neurosci."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1177\/1352458514549397","article-title":"Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis","volume":"21","author":"Olsson","year":"2015","journal-title":"Mult. Scler. J."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Ferreira-Atuesta, C., Reyes, S., Giovanonni, G., and Gnanapavan, S. (2021). The Evolution of Neurofilament Light Chain in Multiple Sclerosis. Front. Neurosci., 15.","DOI":"10.3389\/fnins.2021.642384"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/7\/1050\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:04:56Z","timestamp":1760108696000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/7\/1050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":102,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["medicina60071050"],"URL":"https:\/\/doi.org\/10.3390\/medicina60071050","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,26]]}}}